title: Primary bone natural killer/T cell lymphoma, nasal type without EBV infection: a case report.
abstract: Primary bone NK/T cell lymphoma is very rare. We report a case of 52-year-old man of primary bone NK/T cell lymphoma and then progressed to NK leukemia. The patient had low-grade fever for 4-month, and Ultrasonic B revealed a diffuse hepatosplenomegaly without lymphadenopathy. PET scanning showed increased FDG uptake in many bones of the whole body. The diagnosis was established by bone specimen. These neoplastic cells demonstrated a typical immunophenotype of CD56, CD3, CD2 and MPO positive, and CD5, CD20, CD30, PAX-5, CD4 and CD8 negative. Primary bone ENKTL is very rare; it should be made with the combination of clinical feature, PET-CT image, and pathological characteristics, and should be distinguished from other lymphomas or leukemia involved in bone.
authors.affiliation: Cancer Institute and Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin 300060, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Tian
authors.affiliation: Cancer Institute and Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin 300060, China.
authors.forename: Yafei
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Cancer Institute and Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin 300060, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Cancer Institute and Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin 300060, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Cancer Institute and Hospital of Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin 300060, China.
authors.forename: Yizhuo
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D001859:Bone Neoplasms / Q000473:pathology*; D018450:Disease Progression; D020031:Epstein-Barr Virus Infections; D006801:Humans; D016130:Immunophenotyping; D054391:Lymphoma, Extranodal NK-T-Cell / Q000473:pathology*; D008297:Male; D008875:Middle Aged
keywords: NK/T cell lymphoma; Primary bone; SMILE regimen
references.citation: J Hematol Oncol. 2013;6:86
references.pmid: 24238138
references.citation: Leuk Lymphoma. 2011 Jun;52(6):1041-8
references.pmid: 21599590
references.citation: Cancer Sci. 2012 Jun;103(6):1079-83
references.pmid: 22360679
references.citation: Clin Cancer Res. 2012 Aug 1;18(15):4183-90
references.pmid: 22675173
references.citation: Diagn Pathol. 2012;7:114
references.pmid: 22931631
references.citation: Ann Hematol. 2013 Jan;92(1):89-96
references.pmid: 22992980
references.citation: Diagn Pathol. 2013;8:94
references.pmid: 23773344
references.citation: Eur J Haematol. 2008 Aug;81(2):107-11
references.pmid: 18462253
references.citation: Med Oncol. 2013 Dec;30(4):720
references.pmid: 24062259
references.citation: Ann Hematol. 2014 Nov;93(11):1889-94
references.pmid: 24923454
references.citation: Blood. 2009 Apr 23;113(17):3931-7
references.pmid: 19029440
references.citation: Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):38-44
references.pmid: 17536305
references.citation: Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):318-22
references.pmid: 23426534